{"entity":{"id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","summary":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07160725 by Bristol-Myers Squibb, with 540 participants planned, started 2025-10-15 and due to reach its primary completion in 2028-07-31. Interventions recorded: BMS-986517 and Pumitamig.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07160725","url":"https://clinicaltrials.gov/study/NCT07160725"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07160725","phase":"1/2","setting":"A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","enrolled":540,"outcomes":[]},"route":"/trials/nct07160725/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}